For research use only. Not for therapeutic Use.
(RS)-Butyryltimolol is the racemate of Butyryltimolol. Butyryltimolol, an effective proagent of Timolol, improves the corneal penetration of Timolol[1]. Butyryltimolol is a β-adrenergic blocker[2].
Butyryltimolol, a prodrug of Timolol, is equally effective as 240-min nasolacrimal blockade in enhancing ocular drug absorption[1].
| Catalog Number | I046332 |
| CAS Number | 2320274-78-8 |
| Synonyms | [1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-yl] butanoate |
| Molecular Formula | C17H30N4O4S |
| Purity | ≥95% |
| InChI | InChI=1S/C17H30N4O4S/c1-5-6-14(22)25-13(11-18-17(2,3)4)12-24-16-15(19-26-20-16)21-7-9-23-10-8-21/h13,18H,5-12H2,1-4H3 |
| InChIKey | IGJCFKQCZRWRRM-UHFFFAOYSA-N |
| SMILES | CCCC(=O)OC(CNC(C)(C)C)COC1=NSN=C1N2CCOCC2 |
| Reference | [1]. Chang SC, et al. Relative effectiveness of prodrug and viscous solution approaches in maximizing the ratio of ocular to systemic absorption of topically applied timolol. Exp Eye Res. 1988 Jan;46(1):59-69. [2]. Potter DE, et al. Ocular and cardiac beta-antagonism by timolol prodrugs, timolol and levobunolol. Curr Eye Res. 1988 Aug;7(8):755-9. |
